Vasca raises $20 million for breakthrough product
This article was originally published in Clinica
Vasca, which claims to have developed the first major advance in dialysis access in a decade, has raised nearly $20 million in private equity financing. The round was led by MVM, a UK-based medical venture fund. MVM's CEO, Stephen Reeders, will join the company's board.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.